Syndax Pharmaceuticals (SNDX) Income from Continuing Operations (2015 - 2026)
Syndax Pharmaceuticals' (SNDX) quarterly Income from Continuing Operations came in at 42441000.0 in Q1 2026, up 49.82% year-on-year from 28328388.6 in Q1 2025, and up 27.1% quarter-over-quarter from 58220000.0 in Q4 2025.
Syndax Pharmaceuticals (SNDX) Income from Continuing Operations (2015 - 2026) Analysis & Trends
Syndax Pharmaceuticals' Income from Continuing Operations history runs 12 years deep, the most recent figure standing at 42441000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations rose 49.82% year-over-year to 42441000.0 in Q1 2026; TTM through Mar 2026 was 236865000.0, a 29.91% increase from a year earlier, with the FY2025 full-year figure at 307235000.0, up 46.31% from the prior year.
- Income from Continuing Operations climbed to 42441000.0 in Q1 2026 per SNDX's latest filing, from 58220000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 34552000.0 in Q4 2022 and bottomed at 94134000.0 in Q4 2024.
- The 5-year median for Income from Continuing Operations is 57156000.0 (2023), against an average of 59335588.24.
- Across the five-year window, Income from Continuing Operations tumbled 136.24% in 2022 and soared 49.82% in 2026, its largest moves.
- Year by year, Income from Continuing Operations stood at 34552000.0 in 2022, then plunged by 65.42% to 57156000.0 in 2023, then plunged by 64.7% to 94134000.0 in 2024, then soared by 38.15% to 58220000.0 in 2025, then advanced by 27.1% to 42441000.0 in 2026.
- Per Business Quant, the three latest SNDX Income from Continuing Operations figures stand at 42441000.0 (Q1 2026), 58220000.0 (Q4 2025), and 60457000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Syndax Pharmaceuticals | 1.87 Bn | 1.52 Bn | 53.02 Mn | -42.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -42.44 Mn |
| Dec 31, 2025 | -58.22 Mn |
| Sep 30, 2025 | -60.46 Mn |
| Jun 30, 2025 | -75.75 Mn |
| Mar 31, 2025 | -84.57 Mn |
| Dec 31, 2024 | -94.13 Mn |
| Sep 30, 2024 | -84.16 Mn |
| Jun 30, 2024 | -75.09 Mn |
| Mar 31, 2024 | -81.24 Mn |
| Dec 31, 2023 | -57.16 Mn |
| Sep 30, 2023 | -51.47 Mn |
| Jun 30, 2023 | -50.49 Mn |
| Mar 31, 2023 | -45.92 Mn |
| Dec 31, 2022 | -34.55 Mn |
| Sep 30, 2022 | -35.11 Mn |
| Jun 30, 2022 | -39.75 Mn |
| Mar 31, 2022 | -38.19 Mn |
| Dec 31, 2021 | 95.34 Mn |
| Sep 30, 2021 | -20.60 Mn |
| Jun 30, 2021 | -22.96 Mn |